Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

• Published in: World journal of gastroenterology : WJG Vol. 26; no. 16; pp. 1901 - 1911
• Main Authors: Chen, Hui-Ting, Huang, Hong-Li, Li, Yong-Qiang, Xu, Hao-Ming, Zhou, Yong-Jian
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 28.04.2020
• Subjects: Animals; Anti-Bacterial Agents - administration & dosage; Clinical Trials as Topic; Combined Modality Therapy - methods; Disease Models, Animal; Dysbiosis - complications; Dysbiosis - immunology; Dysbiosis - microbiology; Dysbiosis - therapy; Fecal Microbiota Transplantation; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - immunology; Humans; Intestinal Mucosa - drug effects; Intestinal Mucosa - immunology; Intestinal Mucosa - metabolism; Intestinal Mucosa - microbiology; Minireviews; Non-alcoholic Fatty Liver Disease - immunology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - microbiology; Non-alcoholic Fatty Liver Disease - therapy; Prebiotics - administration & dosage; Probiotics - administration & dosage; Synbiotics - administration & dosage; Treatment Outcome; Gut microbiota; Probiotics; Metabolites; Non-alcoholic fatty liver disease; Fecal microbiota transplantation; Prebiotics

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of health...